Trial Profile
To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2022
Price :
$35
*
At a glance
- Drugs Gabapentin enacarbil (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- 09 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Mar 2018 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.